Publications by the Institutes Staff Members
1. Shpitzer T, Segal K, Schachter J, Hardoff R, Guttman D, Ulanovski D, Feinmesser R, Gutman H. Sentinel node guided surgery for melanoma in the head and neck region. Melanoma Res 14(4):283-287, 2004.
2. Nathansohn N, Schachter J, Gutman H. Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg 140(12):1172-1177, 2005.
3. Wasserberg N, Tulchinsky H, Schachter J, Feinmesser M, Gutman H. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. Eur J Surg Oncol 39(8):851-856, 2004.
4. Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B, Schachter J. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center Isr Med Assoc J 8(3):164-168, 2006.
5. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A, Schachter J. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 177(9):6062-6071, 2006.
6. Hamama-Raz Y, Solomon Z, Schachter J, Azizi E. Objective and subjective stressors and the psychological adjustment of melanoma survivors. Psychooncology 16(4):287-294, 2007.
7. Schachter J, Katz U, Mahrer A, Barak D, David LZ, Nusbacher J, Shoenfeld Y. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann N Y Acad Sci 1110:305-314, 2007.
8. Nathansohn N, Orenstein A, Trau H, Liran A, Schachter J. Pigmented lesions clinic for early detection of melanoma: preliminary results. Isr Med Assoc J 9(10):708-712, 2007.
9. Keshet GI, Goldstein I, Itzhaki O, Cesarkas K, Shenhav L, Yakirevitch A, Treves AJ, Schachter J, Amariglio N, Rechavi G. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 368(4):930-936, 2008.
10. Schallmach E, Sareli R, Besser MJ, Leipsiger S, Hardan I, Treves AJ, Nagler A, Schachter J. Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE Spectra apheresis machine. J Immunother 31(6):563-568, 2008.
11. Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, Sulkes A, Gutman H, Catane R, Schachter J. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma. Oncol Rep 20(6):1533-1538, 2008.
12. Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z, Ramon J, Schachter J. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res 29(1):145-154, 2009.
13. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, Orenstein A, Berger R, Schachter J. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126(2):186-200, 2009.
14. Mashiah J, Brenner S, Pessach Y, Barak V, Schachter J. Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign). Anticancer Res 29(5):1793-1796, 2009.
15. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 32(4):415-423, 2009.
16. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Loewenthal R, Orenstein A, Nagler A, Schachter J. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS ONE 4(5):e5597, 2009.
17. Oved K, Eden E, Akerman M, Noy R, Wolchinsky R, Izhaki O, Schallmach E, Kubi A, Zabari N, Schachter J, Alon U, Mandel-Gutfreund Y, Besser MJ, Reiter Y. Predicting and controlling the reactivity of immune cell populations against cancer. Mol Syst Biol 5:265, 2009.
18. Gluck I, Simon AJ, Catane R, Pfeffer R, Schachter J, Rechavi G, Bar J. Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients. Melanoma Res 19(4):199-202, 2009.
19. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P. Immunotherapy of distant metastatic disease. Ann Oncol 6:vi41-50, 2009.
20. Besser MJ, Schallmach E, Oved K, Treves AJ, Markel G, Reiter Y, Schachter J. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Cytotherapy 11(2):206-217, 2009.
21. Zippel DB, Shapira R, Kuchuk I, Goitein D, Winkler E, Papa MZ, Schachter J. Outcome of thick (> 4 mm) node-negative melanomas. Isr Med Assoc J 11(11):669-672, 2009.
22. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser M, J Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J. Systemic dysregulation of CEACAM1 in the melanoma patients. Cancer Immunol Immunother 59(2):215-230, 2010.
23. Besser MJ, Shapira R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz l, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-Term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res 16(9):2646-2655, 2010.
24. Hershkovitz L, Schachter J, Treves AJ and Besser MJ. Hershkovitz L, Schachter J, Treves AJ and Besser MJ. Focus on Adoptive T cell Transfer Trials in Melanoma Clin and Devel Immunol 2010:260267, 2010.
25. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zickich D, Hershkovitz L, Treves AJ, Shalmon B, Markel G, Schachter J, Besser MJ. Establishment and large-scale expansion of minimally-cultured “Young” Tumor Infiltrating Lymphocytes (TIL) for adoptive transfer therapy. J Immunother 34(2):212-220, 2011.
26. Greenberg E, Hershkovitz l, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of Cancer Aggressive Features in Melanoma Cells by MicroRNAs PLOS ONE 6(4):e18936, 2011.
27. Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G, Eyal E. Mutagen-specific mutation signature determines global microRNA binding. PLoS One 6(11):e27400, 2011.
28. Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisary Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.
29. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, nelson B, Hou J, lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516, 2011.
30. Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: Correlation with clinical and histological survival markers. Invest Opthal Vis Sci 52(13):9368-9372, 2011.
31. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: A diagnostic and therapeutic target. Curr Top Med Chem 12(1):3-10, 2012.
32. Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovsky, Levy D, Cohen CJ, Besser MJ, Schachter J, Markel G. CXCR1 as a novel target for directing reactive T cells towards melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother 61(10):1833-1847, 2012.
33. Ortenberg R, Sapir Y, Raz L, Hershkovitch L, Ben-Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Molecular Cancer Therapeutics 11(6):1300-1310, 2012.
34. Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Scjacjter K. Markel G. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.
35. Sivan S, Susan F, Rona O, Tamar H, Vivian B,, Tamar P, Jacob S, Gal M, Michal L. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2012:290536, 2012.
36. Ortenberg R, Sapir Y, Raz L, Hershkovitch L, Ben-Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Molecular Cancer Therapeutics 11(6):1300-1310, 2012.
37. Gutman H, Ben-Ami E, Shappira-Frommer R, Schachter J. Multidisciplinary management of very advanced stage III and IV melanoma: Proof-of-principle. Oncol Lett 4(2):307-310, 2012.
38. Shapira-Frommer R, Schachter J. Adoptive immunotherapy of advanced melanoma. Curr Treat Options Oncol 13(3):340-353, 2012.
39. Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, Treves AJ, Markel G, Schachter J, Papa MZ. Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and hig-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Exp Ther Med 3(5):898-902, 2012.
40. Vernitsky H, Rechavi O, Rainy N, Besser MJ, Nagar M, Schachter J, lerenthal Y, Ehrilich M, Kloog Y, Goldstein I. Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. J Immunol 189(9):4361-4370, 2012.
41. Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, Van Rooij N, Linnemann C, Van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1(4):409-418, 2012.
42. Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ. Adoptive T-cell transfer in melanoma. Immunotherapy 5(1):79-90, 2013.
43. Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ, Markel G. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One 8(2):e57160, 2013.
44. Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg r Yakirevitch A, Nagler A, Loewenthal R, Schachter J, Markel G. Development of allgeneic NK cell adoptive transfer therapy in metastatic melanoma patients: In vitro preclinical optimization studies. PLoS One 8(3):e57922, 2013.
45. Zikich D, Schachter J, Besser MJ. Immunotherapy for the management of advanced melanoma: The next step. Am J Clin dermatol 14(4):261-272, 2013.
46. Nemlich Y, Greenberg e, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest 123(6):2703-2718, 2013.
47. O'Dady SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, mackiewicz J, Friedlander P, Garber C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, hauschild A. Final results of phase III Symmetry study: Randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment of chemotherapy-naïve patients with advanced melanoma. J Clin Oncol 31(9):1211-1218, 2013.
48. Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, Casadevall A, Dadachova E, Thornton GB. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer 2013:828329, 2013.
49. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparting tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616-622, 2013.
50. Besser MJ, Shapira-Frommer R, Itzhaki O, Traves AJ, Zippel D, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Aptel S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: Intent to treat Analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19(17):4792-4800, 2013.
51. Burazor I, Imazio M, Markel G, Adler Y. Malignant pericardial effusion. Cardiology 124(4):224-232, 2013.
52. Hochberg M, Gilead L, Markel G, Nemlich Y, Feiler Y, Enk CD, Denichenko P, Karni R, Ingber A. Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-l editing events in normal and cancerous human keratinocytes. Arch Dermatol Res 305(6):519-528, 2013.
53. Markel G, Imazio M, Brucato A, Adler Y. Prevention of recurrent pericarditis with colchicines in 2012. Clin Cardiol 36(3):125-128, 2013.
54. Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levi D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: A pilot study. Biomarkers. 18(6):502-508, 2013.
55. Besser MJ. Is there a future for adoptive cell transfer in melanoma patients? Oncoimmunollogy. 2(10):e26098, 2013.
56. Shrot S, Schachter J, Shapira-Frommer R, Besser MJ, Apter S. CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases. Eur Radiol 24(6):1251-1256, 2014.
57. Greenberg E, Jajdu S, Nemlich Y, Cohen R, Itzhaki O, Jacob-Hirsch J, Besser MJ, Schachter J, Markel G. Differential regulation of aggressive features in melanoma cells by member of the miR-17-92 complex. Open Biol 4(6):140030, 2014.
58. Ortenberg R, Galor-Haskel G, Greenberg I, Zamlin B, Sapoznik S, greenberg E, Barshack I, Avivi C, Feiler Y, Zan-bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G. CEACAM1promotes melanoma cell growth through Sox-2. Neoplasia 16(5):451-460, 2014.
59. Greenberg E, Nemlich Y, Markel G. MicroRNAs in Cancer: Lessons from Melanoma. Curr Pharm Des. 20(33):5256-5259, 2014.
60. Robert C, Karaszewski B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos BAJ, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N Engl J Med 372(1):30-39, 2015.
61. Zippel D, Barlev H, Ortenberg R, Barshak I, Schachter J, Markel G.
A longitudinal study of CEACAM1 expression in melanoma disease progression.
Oncology Reports 33(3):1314-1318, 2015.
62. Wainstein A, Algarra SM, Bastholt L, Cinat G, Demidov L, Grob JJ, guo J, Hersey P, Espinosa E, Schachter J, Whitaker D, Quirt I, Hauschild A, Rutkowski P.
Melanoma early detection and awareness: How countries developing melanoma awareness programs could benefit from melanoma-proficient countries.
Am J Ther 22(1):37-43, 2015.
63. Dummer R, Daud A, Puzanov I, Hamid O, Schadendorf D, Robert C, Schachter J, Pavlick A, Gonzalez R, Hodi FS, Cranmer LD, Blank C, O'Day SJ, Ascierto PA, Salama AK, Li NX, Zhou W, Lis J, Ebbinghaus S, Kang PS, Ribas A.
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.
J Transl Med 13:2062, 2015.
64. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrhim N, Ebbinghaus S, Ribas A.
Pembrolizumab versus Ipilimumab in advanced melanoma.
N Engl J Med 372(26):2521-2532, 2015.
65. Ribas A, Puzanov I, Dummer R, Schandendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AKS, Margolin KA, Loquai C, Eigentler TK, Gangadhar TA, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomized, controlled, phase 2 trial.
Lancet Oncology 16(8):908-918, 2015.
66. Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel G.
miR-17 regulates melanoma cell motility by inhibiting the translation ETV1.
Oncotarget 6(22):19006-19016, 2015.
67. Galore-Haskel G, Nemlich Y, Greenberg E, Ashkenazi S, Hakim M, Itzhaki O, Shoshani N, Shapira-Frommer R, Ben-Ami E, Ofek E, Anafi L, Besser MJ, Schachter J, Markel G
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme.
Oncotarget 6(30):28999-29015, 2015.
68. Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, Zikich D, Besser MJ, Schachter J, Markel G.
Serum CEACAM1 elevation correlates with melanoma progression and failure to respond to adoptive cell transfer immunotherapy.
J Immunol Res 2015:902137, 2015.
69. Besser MJ, Shapira-Frommer R, Schachter J.
Tumor-infiltrating lymphocytes: Clinical experience
Cancer J 21(6):465-469, 2015.
70. Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y.
Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.
Oncotarget 7(5):5110-5117, 2016.
71. Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G.
SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.
Oncotarget 7(21):30166-30177, 2016.
72. Markel G, Imazio M, Koren-Morag N, Galore-Haskel G, Schachter J, Besser M, Cumetti D, Maestroni S, Altman A, Shoenfeld Y, Brucato A, Adler Y.
CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis.
Oncotarget 7(14):17885-17895, 2016.
73. Ben-Avi R, Itzhaki O, Simanski D, Zippel D, Markel G, Ben-Nun A, Schachter J, Besser MJ.
Metastatic lung lesions as a preferred resection site for immunotherapy with tumor infiltrating lymphocytes.
J Immunotherapy 39(5):218-222, 2016.
74. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A.
Health-related quality of life in the randomized KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Eur J Cancer 67:46-54, 2016.
75. Haik J, Nardini G, Goldman N, Galore-Haskel G, Harats M, Zilinsky I, Weissman O, Schachter J, Winkler E, Markel G.
Increased serum NKG20D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major bums.
Oncotarget 7(3):2220-2228, 2016.
76. Zikich D, Schachter J, Besser MJ.
Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Immunotherapy 8(1):35-43, 2016.
77. Harats M, Millet E, Jaeger M, Orenstein A, Haik J, Hajdu SD, Markel G, Winkler E, Tessone A.
Adipocytes viability after suction-assisted lipoplasty: Does the technique matter?
Aesthetic Plast Surg 40(4):578-583, 2016.
78. Vitenshtein A, Weisblum Y, Hauka S, Halenius A, Oiknine-Djian E, Tsukerman P, Bauman Y, Bar-On Y, Stem-Ginossar N, Enk J, Ortenberg R, Tai J, Markel G, Blumberg RS, Hengel H, Jonjic S, Wolf DG, Adler H, Kammerer R, Mandelboim O.
CEACAM1-Mediated inhibition of virus production.
Cell Rep 15(11):2331-2339, 2016.
79. Weinstein-Marom H, Pato A, Levin N, Sisid K, Itzhaki O, Besser MJ, Peretz T, Margalit A, Lotem M, Gross G.
Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants.
J Immunother 39(2):60-70, 2016.
80. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbe C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.
Pooled analysis safety profile of Nivolumab and Ipilimumab combination therapy in patients with advanced melanoma.
J Clin Oncol 2017 Sep 15:JCO2016721167. Doi: 10.1200/JCO.2016.72.1167.
81. Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Silevi V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lasimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM.
Adjuvant Dabrafenib plus Trametinib in stage III BRAF-Mutated melanoma.
N Engl J Med 2017 Sep 10. Doi: 10. 1056/NEJMoa1708539.
82. Schachter J, Riba A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.
Pembrolizumab versus Ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomized, open-label phase 3 study (KEYNOTE-006).
Lancet. 2017 Aug 16. Pii: S0140-6736(17)31601-x.doi: 10.1016/\d0140-6736(17)31601.
83. Zippel D, Markel G, ShapirapFrommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S.
Perioperative BRAF inhibitors in locally advanced stage III melanoma.
J Surg Oncol 116(7):856-861, 2017.
84. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandala M, Haanen JBAG, Lebbe C, Mackiewicz A, Rutkowski P, Grobb JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.
Three-year pooled analysis of factors associated with clinical outcomes acress dabrafenib and trametinib combination therapy phase 3 randomised trials.
Eur J Cancer 82:45-55, 2017.
85. Baruch EN, Berg AL, Besser MJ, Schachter J, Markel J.
Adoptive T cell therapy: An overview of obstacles and opportunitis.
Cancer 123(S11):2154-2162, 2017.
86. Blank CU, Larkin J, Arance AM, Hauchild A, Queirolo P, Del Vecchio M, Ascierto PA, Krjsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandala M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders; analysis.
Eur J Cancer 79:176-184, 2017.
87. Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ.
Adoptive cell therapy for metastatic melanoma.
Cancer J 23(1):48-53, 2017.
88. McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Robson S, Gonzalez R, Margolin K.
Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2. Multicentre study.
Ann Oncol 28(3):634-641, 2017.
89. Eisenberg V, Shamalov K, Meir S, Hoogi S, Sarkar R, Pinker S, Markel G, Porgador A, Cohen CJ.
Targeting multiple tumors using T-cells engineered to express a Natural Cytotoxicity Receptor 2-based chimeric Receptor.
Front Immunol 8:1212, 2017.
90. Galore-Haskel G, Baruch EN, Berg AL, Barshack I, Zilinsky I, Avivi C, Besser MJ, Schachter J, Markel G.
Histopathological expression analysis of intercellular adhesion molecule (ICAM-) along development and progression of human melanoma.
Oncotarget 8(59):99580-99586, 2017.
91. Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, Yunger S, Makel G, Schachter J, Besser MJ.
Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation.
Front Immunol 8:1211, 2017.
92. Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.
Eighth American Joint Committee on Cancer (AJCC( melanoma classification: Let us reconsider stage III.
Eur J Cancer 91:168-170, 2018
93. Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
Autoimmune Rev 17(3):284-289, 2018.
94. Maio M, Lewis K, Demidov L, Mandala M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simons B, Ye C, Yan Y, Schadendorf D, BRIM8 Investigators.
Adjuvant Vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): A randomized double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol 19(4):510-520, 2018.
95. Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.
Selumetinib in combination with Dacarbazine in patients with metastatic uveal melanoma: A Phase III, multicenter, randomized trial (SUMIT).
J Clin Oncol 36(12):1232-1239, 2018.
96. Kfir-Ellirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G.
Regulation of CEACAM1 protein expression in the transcription factor ETS-1 in BRAD-Mutant human metastatic melanoma cells.
Neoplasia 20(4):401-409, 2018.
97. Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ.
Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
Cancer Immunol Immunother 67(8):1221-1230, 2018.
98. Nemlich Y, Baruch EN, Besser MJ, Shoshan E, Bar-Eli M, Anafi L, Barshack I, Schachter J, Ortenberg R, Markel G.
ADAR1-mediated regulation of melanoma invasion.
Nat Commun 9(1):2154, 2018.
99. Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Marker G.
Possible immune adverse events as predictors of durable of durable response to BRAF inhibitors in patients with BRAF V600 –mutant metastatic Melanoma.
Eur J Cancer 101:229-235, 2018.
100. Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V, Meir A, Kuby A, Levy M, Zikich D, Zeltzer LA, Brzinger K, Schachter J, Nagler A, Besser MJ, Toren A.
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Am J Hematol 93(12):1485-1492, 2018.
101. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M.
Antitumor activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-011, 002, 006.
Br J Cancer 119(6):670-674, 2018.
102. Eshet Y, Baruch EN, Sapira-Frommer R, Steinberg-Silman Y, Kuznelsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G.
Cancer Immunol Res 2018 Oct 1. Pii: canimm.0659.2017. doi: 10.1158/2326-6066. CI-17-0659.
103. Hauchild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mndala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Hass T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.
Longer follow-up confirms relapse-free survival benefit with adjuvant Dabrafenib plus Trametinib in patients with resected BRAF V600-mutant stage III melanoma.
J Clin Oncol 2018 Oct 22:JCO1801219. DOI: 10. 1200/JCO.18.01219.
104. Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, Peretz T, Lotem M, Gross G.
Potent activation of human T cells by mRNA encoding constittively active CD40.
J Immunol 201(10):2959-2968, 2018.
105. Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, Peretz T, Eisenberg G, Lotem M, Itzhaki O, Besser MJ, Gross G.
Combined expression of genetic adjuvants via mRNA electroporation exerts multiple immunostimulatory effects on antitumor T cells.
J Immunother. Nov 27, 2018. Doi:10.1097/CJI.0000000000000252.
